Education
About Us
Working with TipRanks
Follow Us
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
Total Valuation
LAVA Therapeutics has a market cap or net worth of $41.30M. The enterprise value is -$20.66M.
Market Cap$41.30M
Enterprise Value-$20.66M
Share Statistics
LAVA Therapeutics has 26,305,296 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,305,296
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
LAVA Therapeutics’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -44.77%.
Return on Equity (ROE)-0.91
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-44.77%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee352.41K
Profits Per Employee-738.65K
Employee Count34
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of LAVA Therapeutics is ―. LAVA Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.92
Price to FCF―
Price to Operating Cash Flow-1.93
PEG Ratio―
Income Statement
In the last 12 months, LAVA Therapeutics had revenue of 11.98M and earned -25.11M in profits. Earnings per share was -0.94.
Revenue11.98M
Gross Profit11.98M
Operating Income-29.69M
Pretax Income-24.48M
Net Income-25.11M
EBITDA-23.50M
Earnings Per Share (EPS)-0.94
Cash Flow
In the last 12 months, operating cash flow was -21.76M and capital expenditures -23.00K, giving a free cash flow of -21.78M billion.
Operating Cash Flow-21.76M
Free Cash Flow-21.78M
Free Cash Flow per Share-0.83
Dividends & Yields
LAVA Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-7.65%
50-Day Moving Average1.46
200-Day Moving Average1.29
Relative Strength Index (RSI)60.47
Average Volume (3m)164.16K
Important Dates
LAVA Therapeutics upcoming earnings date is Nov 12, 2025, Before Open (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
LAVA Therapeutics as a current ratio of 4.40, with Debt / Equity ratio of 0.00%
Current Ratio4.40
Quick Ratio4.40
Debt to Market Cap0.19
Net Debt to EBITDA1.27
Interest Coverage Ratio-57.66
Taxes
In the past 12 months, LAVA Therapeutics has paid 630.00K in taxes.
Income Tax630.00K
Effective Tax Rate-0.03
Enterprise Valuation
LAVA Therapeutics EV to EBITDA ratio is 0.18, with an EV/FCF ratio of 0.22.
EV to Sales-0.35
EV to EBITDA0.18
EV to Free Cash Flow0.22
EV to Operating Cash Flow0.22
Balance Sheet
LAVA Therapeutics has $56.17M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$56.17M billion.
Cash & Marketable Securities$56.17M
Total Debt$0.00
Net Cash-$56.17M
Net Cash Per Share-$2.14
Tangible Book Value Per Share$1.03
Margins
Gross margin is -398.54%, with operating margin of -247.81%, and net profit margin of -209.60%.
Gross Margin-398.54%
Operating Margin-247.81%
Pretax Margin-204.34%
Net Profit Margin-209.60%
EBITDA Margin-196.14%
EBIT Margin-200.04%
Analyst Forecast
The average price target for LAVA Therapeutics is $1.37, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.37
Price Target Upside-12.74% Downside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast-32.55%
EPS Growth Forecast-15.83%